Comparison Overview

Eurofins

VS

Roche

Eurofins

Val Fleuri 23, Luxembourg, 1526, LU
Last Update: 2026-04-01
View Profile
Between 750 and 799
https://www.eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 25,817
Subsidiaries: 21
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Roche

Grenzacherstrasse, Switzerland 🇨🇭 , 4070, CH
Last Update: 2026-04-01
Between 800 and 849
http://www.roche.com/

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 103,689
Subsidiaries: 51
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/eurofins.jpeg
Eurofins
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/roche.jpeg
Roche
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Eurofins
100%
Compliance Rate
0/4 Standards Verified
Roche
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Eurofins in 2026.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Roche in 2026.

Incident History — Eurofins (X = Date, Y = Severity)

Eurofins cyber incidents detection timeline including parent company and subsidiaries

Incident History — Roche (X = Date, Y = Severity)

Roche cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/eurofins.jpeg
Eurofins
Incidents

No Incident

https://images.rankiteo.com/companyimages/roche.jpeg
Roche
Incidents

No Incident

FAQ

Roche company demonstrates a stronger AI Cybersecurity Score compared to Eurofins company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Roche company has disclosed a higher number of cyber incidents compared to Eurofins company.

In the current year, Roche company and Eurofins company have not reported any cyber incidents.

Neither Roche company nor Eurofins company has reported experiencing a ransomware attack publicly.

Neither Roche company nor Eurofins company has reported experiencing a data breach publicly.

Neither Roche company nor Eurofins company has reported experiencing targeted cyberattacks publicly.

Neither Eurofins company nor Roche company has reported experiencing or disclosing vulnerabilities publicly.

Neither Eurofins nor Roche holds any compliance certifications.

Neither company holds any compliance certifications.

Roche company has more subsidiaries worldwide compared to Eurofins company.

Roche company employs more people globally than Eurofins company, reflecting its scale as a Biotechnology Research.

Neither Eurofins nor Roche holds SOC 2 Type 1 certification.

Neither Eurofins nor Roche holds SOC 2 Type 2 certification.

Neither Eurofins nor Roche holds ISO 27001 certification.

Neither Eurofins nor Roche holds PCI DSS certification.

Neither Eurofins nor Roche holds HIPAA certification.

Neither Eurofins nor Roche holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability was found in Nothings stb up to 1.26. Impacted is the function stbtt_InitFont_internal in the library stb_truetype.h of the component TTF File Handler. Performing a manipulation results in out-of-bounds read. Remote exploitation of the attack is possible. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:N/A:P
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain an out-of-bounds read in VS6ComFile!get_macro_mem_COM. Opening a crafted V7 file may lead to information disclosure from the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain a stack-based buffer overflow in VS6ComFile!CSaveData::_conv_AnimationItem. Opening a crafted V7 file may lead to arbitrary code execution on the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain an out-of-bounds read vulnerability in VS6MemInIF!set_temp_type_default. Opening a crafted V7 file may lead to information disclosure from the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain an out-of-bounds read vulnerability in VS6ComFile!load_link_inf. Opening a crafted V7 file may lead to information disclosure from the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References